---
document_datetime: 2025-11-12 12:09:35
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/glivec-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: glivec-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6822089
conversion_datetime: 2025-12-20 07:15:40.137278
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Glivec

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA / EMA/VR/0000309417 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality | 06/11/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                                  |                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000290092 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.5 of the SmPC in order to add drug-drug interaction information with methotrexate based on reports of delayed excretion of high dose methotrexate when concomitantly administered with imatinib and improvement of methotrexate clearance when imatinib treatment was withheld. In addition, the MAH took the opportunity to introduce minor editorial and administrative changes to the PI, including an update to the list of local representatives in the Package Leaflet. | 16/10/2025 | SmPC, Annex II and PL            | SmPC new text: Imatinib may have the potential to delay the clearance of methotrexate, particularly when methotrexate is used at high doses (>500 mg/m2). Caution is recommended when Glivec is given concomitantly with methotrexate. For more information, please refer to the Summary of Product Characteristics. |
| Variation type IB / EMA/VR/0000282643 | This was an application for a group of variations. C.I.7 Deletion of: - C.I.7.a a pharmaceutical form - Accepted A. ADMINISTRATIVE CHANGES - A.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/08/2025 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|